This section of the global Janssen website provides a company overview in several languages. It is not targeted to any specific audience or country. Click here for country- and region-specific information of interest.
Find out how Janssen collaborates with partners around the world to solve problems and find transformational solutions.
See More >
Collaborating in more than 150 countries. By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com. These sections or websites are governed by their own Legal and Privacy Policies.
Welcome to the Janssen Immunology ACG 2020 Newsroom! Please see below for the latest meeting news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines for Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis.
Janssen’s Commitment to IBD
A Message from our Gastroenterology Leaders
We are honored to be sharing our latest research in IBD at this year’s virtual American College of Gastroenterology (ACG) Annual Scientific Meeting. At Janssen, we remain steadfast in our commitment in IBD by seeking out solutions, uncovering novel treatment approaches, and working collaboratively with the most passionate and brightest minds to deliver transformational therapies for IBD patients. We understand there is still a large unmet need in IBD, and that many patients around the world are struggling to find the right treatment, maintain symptom relief, and achieve remission. These unmet needs are what motivate and drive us to continue to pioneer in the area of IBD, so that people around the world can live free from disease.
Learn more about our research at ACG below!
Jan Wehkamp, M.D. Disease Area Leader
View Jan's profile
Albert Lee Disease Area Commercial Leader
View Albert's profile
Driven by a relentless dissatisfaction with the status quo, we will redefine treatments for immune diseases by delivering transformational and accessible therapies and regimens to patients with autoimmune disease.